Announced Wed, 19 Aug · 19:37 IST
Strides gets USFDA clearance for Bengaluru plant
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.0%1-day move
₹955.00
prior close
₹986.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+5.1+5.8+5.7+4.3+3.0—————————
Up moveDown movePending
AI summary
Strides received the USFDA Establishment Inspection Report (EIR) for its flagship Bengaluru facility, closing the May 2026 cGMP inspection with a Voluntary Action Indicated (VAI) classification. The inspection had five Form 483 observations, which the company addressed. VAI means no further regulatory action is required. The facility makes tablets, capsules and oral liquids for regulated and international markets.
Likely market impact
Positive: flagship plant cleared for US supplies; strengthens regulatory track record and supports future growth in regulated markets.